Anti-CTLA4 Immunotherapy in Mouse Tumor Models
Author Information
Author(s): Jonas Persson, Ines Beyer, Roma Yumul, ZongYi Li, Hans-Peter Kiem, Steve Roffler, André Lieber
Primary Institution: University of Washington
Hypothesis
How does anti-CTLA4 therapy perform in tolerized versus non-tolerized mouse tumor models?
Conclusion
Anti-CTLA4 therapy was ineffective in the tolerized MMC model but showed efficacy in the non-tolerized TC-1 model.
Supporting Evidence
- Anti-CTLA4 therapy delayed tumor growth in the TC-1 model.
- Anti-CTLA4 therapy had no effect in the MMC model.
- Hematopoietic stem cell delivery of anti-CTLA4 was detrimental in both models.
Takeaway
This study looked at a cancer treatment called anti-CTLA4 and found it works well in some mouse models but not in others that are more like real human cancers.
Methodology
The study used two mouse tumor models to test the effects of anti-CTLA4 therapy, comparing systemic application and gene delivery methods.
Potential Biases
Potential bias in the interpretation of results due to the use of animal models.
Limitations
The study's findings may not directly translate to human cancer treatment due to differences in immune response.
Participant Demographics
C57Bl/6 and neu-transgenic mice were used in the study.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website